Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11816531rdf:typepubmed:Citationlld:pubmed
pubmed-article:11816531lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0002335lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0085174lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0032975lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0546824lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:11816531lifeskim:mentionsumls-concept:C0439611lld:lifeskim
pubmed-article:11816531pubmed:dateCreated2001-12-5lld:pubmed
pubmed-article:11816531pubmed:abstractTextAlthough the use of prostaglandin plays an important role in the reproductive human physiology, it is still controversial in the reproductive field. Ovarian stimulation as well as intrauterine insemination increased the reproductive goals in certain group of patients. The objective of the present study was to evaluate the prostaglandin effect (misoprostol) in patients under ovarian stimulation and intrauterine insemination and their final outcome in the clinical pregnancy rate. There were a total of 59 ovarian stimulated cycles, the study group (n = 29) received 200 micrograms of prostaglandin E1 (misoprostol) intravaginal after IUI, compared with the control group (n = 30). Demographic characteristics were similar in both groups. There were no differences in age, FSH. LH and E2, hCG day and number of ampoules between groups. However, a significant pregnancy rate was observed between groups (31% study group vs. 20% control group). We concluded that prostaglandin application in stimulated cycles under intrauterine insemination remain a beneficial effect showing in the pregnancy outcome.lld:pubmed
pubmed-article:11816531pubmed:languagespalld:pubmed
pubmed-article:11816531pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11816531pubmed:citationSubsetIMlld:pubmed
pubmed-article:11816531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11816531pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11816531pubmed:statusMEDLINElld:pubmed
pubmed-article:11816531pubmed:monthSeplld:pubmed
pubmed-article:11816531pubmed:issn0300-9041lld:pubmed
pubmed-article:11816531pubmed:authorpubmed-author:KarchmerSSlld:pubmed
pubmed-article:11816531pubmed:authorpubmed-author:CarballoEElld:pubmed
pubmed-article:11816531pubmed:authorpubmed-author:BarrosoGGlld:pubmed
pubmed-article:11816531pubmed:authorpubmed-author:KablyAAlld:pubmed
pubmed-article:11816531pubmed:authorpubmed-author:CastelazoEElld:pubmed
pubmed-article:11816531pubmed:issnTypePrintlld:pubmed
pubmed-article:11816531pubmed:volume69lld:pubmed
pubmed-article:11816531pubmed:ownerNLMlld:pubmed
pubmed-article:11816531pubmed:authorsCompleteYlld:pubmed
pubmed-article:11816531pubmed:pagination346-50lld:pubmed
pubmed-article:11816531pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:meshHeadingpubmed-meshheading:11816531...lld:pubmed
pubmed-article:11816531pubmed:year2001lld:pubmed
pubmed-article:11816531pubmed:articleTitle[A prospective randomized trial of the impact of misoprostol (PgE1) on pregnancy rate after intrauterine insemination (IUI) therapy: a preliminary report].lld:pubmed
pubmed-article:11816531pubmed:affiliationCentro Especializado Para la Atención de la Mujer, Unidad de Reproducción Asistida, Hospital Angeles de las Lomas.lld:pubmed
pubmed-article:11816531pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11816531pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:11816531pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:11816531pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:11816531pubmed:publicationTypeRandomized Controlled Triallld:pubmed